

1. (Amended) A medicament for protection against thrombotic diseases, comprising at least one active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes.
2. (Amended) The medicament as claimed in claim 1, wherein the at least one active principle is an antibody.
3. (Amended) The medicament as claimed in claim 1, wherein the at least one active principle is monoclonal antibody JAQ1.
4. (Amended) The medicament as claimed in claim 1, wherein the collagen receptor on thrombocytes is GPVI.
5. (Amended) The medicament as claimed in claim 1, wherein the at least one active principle is humanised monoclonal antibody JAQ1.
6. (Amended) A diagnostic agent for the determination of the expression rate of a collagen receptor GPVI, comprising at least one labelled antibody chosen from a monoclonal antibody and a polyclonal antibody, wherein the at least one labelled antibody is directed against a GPVI epitope.
7. (Amended) A method for the determination of the expression rate of a collagen receptor GPVI in blood of a patient comprising:
 - a) incubating a sample of the blood with a solid carrier on which antibody JAQ1 is fixed,
 - b) washing the solid carrier,
 - c) incubating the washed solid carrier with a second labelled antibody JAQ1,
 - d) washing the carrier again, and
 - e) measuring a signal of the second labelled antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Q2
8. (Amended) The method as claimed in claim 7, wherein the signal is measured in a flow-cytometer using a fluorescence-labelled monoclonal JAQ1 antibody.

10. (Amended) Monoclonal antibody that binds to the same or a similar epitope of a collagen receptor for thrombocytes as monoclonal antibody JAQ1.

11. (Amended) A method for producing a medicament against thrombotic diseases comprising providing at least one active principle that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes.

Q3
12. (Amended) The method as claimed in claim 11, wherein the at least one active principle is a monoclonal antibody.

13. (Amended) The method as claimed in claim 11, wherein the at least one active principle is monoclonal antibody JAQ1.

Please add new claims 14-16 as follows:

14. (New) The diagnostic agent as claimed in claim 6, wherein the at least one labelled monoclonal antibody is JAQ1.

15. (New) A method for the determination of the expression rate of a collagen receptor GPVI in blood of a patient comprising:

- a) fixing a sample of the blood on a solid carrier,
- b) treating the fixed sample with a labelled antibody JAQ1 alone or in mixture with an unlabelled antibody JAQ1, and
- c) detecting the labelled antibody JAQ1.

16. (New) A method for the determination of the expression rate of a collagen receptor GPVI in blood of a patient comprising:

- a) fixing monoclonal antibody JAQ1 on a solid carrier,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com